目的：探讨疏血通注射液联合玻璃体腔内注射雷珠单抗、激光光凝治疗视网膜分支膜静脉阻塞(branch retinal vein occlusion，BRVO)继发黄斑水肿(macular edema，ME)的疗效。

方法：将2015-01/2016-12就诊的BRVO继发ME患者70例70眼采用随机数字表法分为对照组和观察组，每组各35例35眼。对照组行玻璃体腔内注射雷珠单抗联合激光光凝治疗，观察组在对照组基础上加用疏血通注射液。比较两组治疗3mo临床疗效、并发症。治疗1wk，1、3mo复查最佳矫正视力(BCVA，LogMAR)、黄斑中心凹视网膜厚度(central macular thickness，CMT)。

结果：观察组总有效率为91%，略高于对照组的80%，但差异无统计学意义(P>0.05)； 观察组显效率为43%，高于对照组的20%，差异有统计学意义(P<0.05)。两组治疗后1wk，1、3mo BCVA水平、CMT均降低，较治疗前比较差异均有统计学意义(P<0.05)； 观察组治疗后1wk，1、3mo LogMAR BCVA水平、CMT低于对照组同期，差异均有统计学意义(P<0.05)。两组并发症发生率比较差异无统计学意义(P>0.05)。

结论：疏血通注射液联合玻璃体腔内注射雷珠单抗、激光光凝治疗BRVO继发ME可有效降低CMT，提高视力水平，且安全性高。

METHODS: Totally 70 patients(70 affected eyes)with ME secondary to BRVO treated from January 2015 to December 2016 were randomly divided into the control group and the observation group by random number table method, 35 patients(35 affected eyes)in each group. The control group were treated by intravitreal injection of ranibizumab and laser photocoagulation, and on the basis, the observation group were treated with Shuxuetong injection. The clinical curative effect and complications were compared between the two groups. At 1wk, 1 and 3mo after treatment, the best corrected visual acuity(BCVA)and central retinal thickness(CRT)were checked again.

RESULTS: The total effective rate of treatment in the observation group was slightly higher than that in the control group(91% vs 80%; P>0.05)while the markedly effective rate in the observation group was higher than that in the control group(43% vs 20%; P<0.05). At 1wk, 1 and 3mo after treatment, BCVA and CMT in the two groups decreased(P<0.05), and they were lower in the observation group than the control group at the same time point(P<0.05). There was no significant difference in the incidence of complications between the two groups(P>0.05).

CONCLUSION: The treatment of ME secondary to BRVO with Shuxuetong injection combined with intravitreal injection of ranibizumab and laser photocoagulation can effectively reduce CRT and improve visual acuity, with high safety.